Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Herpesvirus DNA-directed DNA polymerase is a fundamental enzyme required for the replication of the double-stranded DNA genomes of viruses within the Herpesviridae family, including Herpes Simplex Virus (HSV), Varicella-Zoster Virus (VZV), and Cytomegalovirus (CMV) [3, 5]. This enzyme belongs to the Family B DNA polymerases and typically operates as a complex comprising a catalytic subunit and a processivity factor that enhances the enzyme's ability to synthesize long DNA strands without dissociating [3, 5]. The catalytic subunit exhibits both 5'-3' polymerase activity for DNA synthesis and 3'-5' exonuclease activity for proofreading, which is vital for maintaining viral genetic stability [3, 7]. As an essential component of the viral lytic cycle, it serves as the primary target for the majority of approved anti-herpetic medications [1, 3]. Drugs such as acyclovir and ganciclovir act as prodrugs that, once activated by viral kinases, competitively inhibit the polymerase and induce premature chain termination of the nascent viral DNA [1, 2]. Other inhibitors, like foscarnet, bind directly to the pyrophosphate-binding site of the enzyme to block its activity [1, 6]. Despite the success of these therapies, the development of resistance through mutations in the polymerase gene is a major concern, especially during long-term treatment in immunocompromised individuals [3, 4].
The primary mechanism of action for drugs targeting this enzyme involves the use of nucleoside or nucleotide analogues that act as competitive inhibitors of the viral DNA polymerase and/or as DNA chain terminators after being incorporated into the growing viral DNA strand [1, 2, 3]. Additionally, pyrophosphate analogues like foscarnet directly inhibit the enzyme by binding to its pyrophosphate-binding site, preventing the release of pyrophosphate from deoxynucleoside triphosphates and halting DNA synthesis [1, 6].
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Herpesvirus DNA-directed DNA polymerase (Pol).